Cocrystal pharma receives uk mhra authorization to initiate its phase 2a influenza human challenge trial with oral pb2 inhibitor cc-42344

Bothell, wash., oct. 31, 2023 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (cocrystal or the company) announces receipt of authorization from the united kingdom medicines and healthcare products regulatory agency (mhra) to initiate a phase 2a human challenge trial with its broad-spectrum, oral pb2 inhibitor cc-42344 as a potential treatment for pandemic and seasonal influenza a. cocrystal expects to begin treating influenza-infected subjects in this trial during the fourth quarter of 2023.
COCP Ratings Summary
COCP Quant Ranking